You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 022118


✉ Email this page to a colleague

« Back to Dashboard


NDA 022118 describes FENOGLIDE, which is a drug marketed by Salix and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the FENOGLIDE profile page.

The generic ingredient in FENOGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.
Summary for 022118
Tradename:FENOGLIDE
Applicant:Salix
Ingredient:fenofibrate
Patents:4
Pharmacology for NDA: 022118
Medical Subject Heading (MeSH) Categories for 022118
Suppliers and Packaging for NDA: 022118
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FENOGLIDE fenofibrate TABLET;ORAL 022118 NDA AUTHORIZED GENERIC Amneal Pharmaceuticals of New York LLC 0115-1522 0115-1522-10 90 TABLET in 1 BOTTLE (0115-1522-10)
FENOGLIDE fenofibrate TABLET;ORAL 022118 NDA AUTHORIZED GENERIC Amneal Pharmaceuticals of New York LLC 0115-1523 0115-1523-10 90 TABLET in 1 BOTTLE (0115-1523-10)

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength40MG
Approval Date:Aug 10, 2007TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Dec 9, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Oct 1, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
Patent:⤷  Sign UpPatent Expiration:Oct 1, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

Expired US Patents for NDA 022118

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 ⤷  Sign Up ⤷  Sign Up
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 ⤷  Sign Up ⤷  Sign Up
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 ⤷  Sign Up ⤷  Sign Up
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-002 Aug 10, 2007 ⤷  Sign Up ⤷  Sign Up
Salix FENOGLIDE fenofibrate TABLET;ORAL 022118-001 Aug 10, 2007 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.